HDAC Inhibitors Market

HDAC Inhibitors Market - Size, Share, Growth,
Outlook, and Opportunity Analysis, 2018-2026
HDAC inhibitors refers to the class of anti-cancer agents that play a vital role in non-epigenetic or
epigenetic regulation, inducing cell cycle arrest, apoptosis, and death of cancer cells. Histone
deacetylase inhibitors (HDACi) are promising therapeutics, which have already shown potential for
oncological applications such as cancer detection, diagnosis, and prognosis. For instance, Vorinostat
(Merck & Co. Inc.) is a novel drug used in the management of cutaneous T cell lymphoma during
disease progression or relapse or while undergoing treatment. Current candidates are demonstrating
successful pre-clinical and clinical trials for various other diseases such as neurological ailments,
heart diseases, and HIV infections.
Request Sample Copy of Research Report:
Numerous classes of Histone deacetylase inhibitors, include benzamides such as MS-275, organic
hydroxamic acids such as TSA and SAHA, cyclic tetrapeptides such as sulfonamide anilides and
trapoxin, and short-chain fatty acids such as valproic acid and butyrates. Increasing number of
applications in different therapeutic areas such as neurodegenerative diseases, including
Huntington’s and Alzheimer’s disease, Polycythemia vera, inflammation, and essential
Thrombocythemia, Myelofibrosis, is expected to fuel the demand for HDAC inhibitors in the near
Increasing R&D activities for cancer is expected to boost HDAC inhibitors market
during the forecast period
In February 2015, Novartis received the U.S. FDA approval for Farydak capsules along with
dexamethasone and bortezomib*, for patients suffering from multiple myeloma, who previously
received minimum two regimens. FDA approval of few HDAC inhibitors for cancer treatment has
created interest in finding new products as potential anti-cancer drugs. Moreover, increasing
R&D activities for the treatment of cancer and other neurological disorders is one of the prime
factors responsible for growth of the HDAC inhibitors market. Around 350 clinical trials were
carried out or under process using HDACi as single therapeutic or along with other targeted
agents against different human diseases. However, uncertainty issues about the therapeutic
potential of HDAC inhibitors and stringent reimbursement policies is expected to impede growth
of the market in near future. For instance, there can be significant delays in gaining
reimbursement and coverage for newly approved drugs by FDA or other foreign regulatory
Report includes chapters which deeply display the following deliverable about industry :
• HDAC Inhibitors Market Research Objective and Assumption
• HDAC Inhibitors Market Purview - Report Description, Executive Summary, and Coherent
Opportunity Map (COM)
• HDAC Inhibitors Market Dynamics, Regulations, and Trends Analysis - Market Dynamics,
Regulatory Scenario, Industry Trend, Merger and Acquisitions, New system Launch/Approvals, Value
Chain Analysis, Porter’s Analysis, and PEST Analysis
• Global HDAC Inhibitors Market, By Regions
• HDAC Inhibitors Market Competition by Manufacturers including Production, Share, Revenue,
Average Price, Manufacturing Base Distribution, Sales Area and Product Type.
• HDAC Inhibitors Market Manufacturers Profiles/Analysis including Company Basic Information,
Manufacturing Base and Its Competitors.
• HDAC Inhibitors Market Manufacturing Cost Analysis including Key Raw Materials and Key
Suppliers of Raw Materials.
• Industrial Chain, Sourcing Strategy and Downstream Buyers including Upstream Raw Materials
Sourcing and Downstream Buyers
• Marketing Strategy Analysis, Distributors/Traders including Marketing Channel, Market Positioning
and Distributors/Traders List.
• Market Effect Factors Analysis including Technology Progress/Risk, Consumer Needs/Customer
Preference Change and Economic/Political Environmental Change.
• HDAC Inhibitors Market Forecast including Production, Consumption, Import and Export Forecast
by Type, Applications and Region.
• Research Findings and Conclusion
Major players operating in the HDAC inhibitors market include AbbVie, Celgene,
Celldex, Chipscreen, Chroma Therapeutics, GSK, Merck, Novartis, Onxeo, Syndax, and
Spectrum Pharmaceuticals.
Inquire Here Before Purchase:
Market Taxonomy
On the basis of application, the HDAC inhibitors market is segmented into:
• Oncology
• Neurology
• Other
On the basis of end user, the HDAC inhibitors market is segmented into:
• Hospitals
• Oncology Clinics
• Others
About Coherent Market Insights
Coherent Market Insights is a prominent market research and consulting firm offering action-ready
syndicated research reports, custom market analysis, consulting services, and competitive analysis
through various recommendations related to emerging market trends, technologies, and potential
absolute dollar opportunity.
Contact Us
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: [email protected]